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This study combined a variety of methods to determine the prevalence of cystic fibrosis in the European Union. The results of literature
reviews, surveys, and registry analyses revealed a mean prevalence of 0.737/10,000 in the 27 EU countries, which is similar to the value of 0.797
in the United States, and only one outlier, namely the Republic of Ireland at 2.98.
© 2008 Published by Elsevier B.V. on belalf of European Cystic Fibrosis Society.Keywords: Cystic fibrosis; Prevalence; Incidence; Europe; European UnionAlthough the incidence of cystic fibrosis (CF) has been
generally well defined throughout Europe in recent years from
newborn screening programs [1], its prevalence is more difficult
to ascertain for a number of reasons, including the fact that the
medical/scientific literature and patient registries vary in quality.
Thus, the prevalence of CF in the European Union (EU) has not
been determined with sufficient accuracy in its 27 constituent
countries. During the past two decades, care for European
patients with CF has been increasingly organized in specialized
centers and diagnoses generally reported to regional or national
registries. This facilitates determination of the prevalence of CF
for most European countries. The available data, however, show
substantial variations, although all of the information suggests a
prevalence that is much lower than 5 per 10,000 population, the
limit for “orphan disease” designation. [2]
A quantitatively and geographically comprehensive assess-
ment of CF in Europe was performed and published by Farrell's
research team in collaboration with Milan Macek [3]. Their
project was designed to determine the worldwide distribution of
CFTR mutations and the number of patients so assessed in each
country. This article [3] was published after an exhaustive
literature search that included 33 European countries and 115
references which are available online. Subsequently, only a
limited number of other articles have appeared, but the CF⁎ Tel.: +1 608 263 9094; fax: +1 608 263 2820.
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doi:10.1016/j.jcf.2008.03.007patient registries of European countries have improved
significantly during the past few years. Furthermore, many
European countries now require patients to be registered at CF
centers in order to receive reimbursed care. These developments
made it possible to determine the prevalence of CF throughout
the EU with estimation required in one country with only
limited information. This brief report describes the multiple
methods used to determine CF prevalence among Europeans
and data from the 27 EU countries, as well as incidence data
where available.
1. Methods
For this evaluation of CF prevalence in the 27 EU countries,
after an uninformative EMBASE.com search, a combination of
three methods was used: 1) a PubMed literature search from
1990 through 2006; 2) a review of CF patient registry data
available from the European Cystic Fibrosis Society and
individual countries, generally for the year 2004; and 3) a
survey of CF leaders in 18 European countries accomplished by
exchanging e-mail communications. In addition, where no
reliable CF patient information could be found for the country
(i.e., Malta), the number of CF patients was estimated/predicted
by multiplying the average prevalence determined in other
European countries times the population reported in 2004. The
population values for each country were obtained from the U.S.
Census Bureau website for the last complete year available atropean Cystic Fibrosis Society.
Table 1
Population and prevalence of patients with CF in E.U. countries
Population
in 2004
(thousands)
# CF
patients
CF
prevalence
(per 10,000)
Estimated
CF
incidence
Source(s)
Austria 8,175 686 0.839 1:3500 Ia, [1]
Belgium 10,348 1065 1.03 1:2850 Ib, IIa, [13,14]
Bulgaria 7,518 170 0.226 1:2500 [13]
Cyprus 776 26 0.335 1:7914 [15]
Czech
Republic
10,246 570 0.556 1:2833 Ic, IIa, [14,16]
Denmark 5,413 412 0.761 1:4700 IIa, [14,17,18]
Estonia 1,342 83 0.618 1:4500 [17]
Finland 5,215 64 0.123 1:25000 Id, [17,19]
France 60,424 4533 0.750 1:4700 Ie, IIa, IIe, [1]
Germany 82,425 6835 a 0.829 a 1:3300 If, IIa,
[14,16,20]
Greece 10,648 555 0.521 1:3500 Ig, [14]
Hungary 10,032 410 0.409 Ih
Ireland 3,970 1182 2.98 1:1353 Ii, IIb, [8]
Italy 58,057 5064 0.872 1:4238 IIc, [21]
Latvia 2,306 24 0.104 [7]
Lithuania 3,608 47 0.130 [7]
Luxembourg 463 20 0.431 [7]
Malta 397 23 0.579 IV
Netherlands 16,318 1275 0.781 1:4750 IIa, [22]
Poland 38,580 987 0.256 1:5000 Ij, [1]
Portugal 10,524 285 a 0.271 a 1:6000 Ik,[7]
Romania 22,356 238 0.106 1:2056 [23]
Slovakia 5,424 340 0.627 1:1800 IIa, [24]
Slovenia 2,011 66 0.328 1:3000 [7,25]
Spain 40,281 2200 a 0.546 a 1:3750 Il, [13,14]
Sweden 8,986 362 0.403 1:5600 IIa, [26]
United
Kingdom
60,271 8284 1.37 1:2381 Im, IIa, IId, [9]
I = survey data.
a. Austria (Manfred Götz).
b. Belgium (Jean-Jacques Cassiman).
c. Czech Republic (Milan Macek).
d. Finland (Leena Jokinen).
e. France (Virginie Scotet).
f. Germany (Gerd Döring and Andreas Reimann).
g. Greece (Maria Tzetis).
h. Hungary (Klara Holics).
i. Ireland (Linda Foley).
j. Poland (Dorota Sands).
k. Portugal (Maria Celeste Barreto and Margarida Amaral).
l. Spain (Silvia Gartner and Manuel Sanchez-Solis de Querol).
m. United Kingdom (Anil Mehta).
II = registry information.
a. European CF Registry (provided by Karleen De Rijcke).
b. The CF Registry of Ireland (provided by Linda Foley).
c. Registro Italiano Fibrosi Cistica (provided and translated by Carlo Castellani).
d. UKCF Database (provided by Anil Mehta).
e. Observatoire National de la Mucoviscidose (provided by Virginie Scotet).
III = extrapolation (see text).
–Arabic numerals correspond to references in bibliography.
a Revised from EU submission to COMP.
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closely to the period that most of the information on reported CF
patients was obtained. To ensure accuracy, these population
values were compared with data published by Eurostat, which is
the Statistical Office of the European Communities [5]. The
average difference in the population values listed by the U.S.
Census Bureau and the values published by Eurostat was 1.43%
for the 27 countries. Thus, the U.S. Census Bureau figures were
considered sufficiently accurate for the purposes of this study.
In addition to identifying data on CF patient numbers re-
ported and/or registered in EU countries, the literature review
included a survey of reported CF incidence values. Whenever
possible, birth incidence values based on newborn screening
experience were obtained as the likely most accurate data [1].
The validity of the prevalence data was established by ex-
amining survey results for potential biases and demonstrating
comparability when several sources were available. Instead of
merging such data or calculating a weighted average, it was
decided to accept and report the highest number of patients
because of the probability of under-reporting [6].
2. Results
The accompanying table provides a summary of available
information for EU countries during 2004 and includes pop-
ulation, the number of reported CF patients, calculated prev-
alence, estimated prevalence, incidence reported in the literature
(birth incidence, whenever available), and source of the data. All
CF prevalence values were data-driven determinations from the
literature and/or registries, and generally from multiple sources,
except for Malta where the prevalence was estimated from the
population and mean EU prevalence; because the population of
Malta at 397,000 is only 0.8 % of the EU total, this estimation
has a negligible effect on overall precision (Table 1).
The CF incidence data of the table were derived from the
most accurate sources that could be found in the literature and
are expressed in the conventional fashion as CF cases diagnosed
in relationship to livebirths. Whenever there was information
derived from nationwide newborn screening, those values were
selected as presumably the most accurate. This explains why the
incidence data listed for some countries such as France (1:4700)
vary from the older values reported by Bobadilla et al. [3]. For
other countries such as the Czech Republic more analysis of
birth incidence based on newborn screening outcome data will
be needed to insure accuracy.
Combining all EU countries, there were 35,806 CF patients
identified in a total population during 2004 of 486,114,000,
resulting in a mean prevalence of 0.737 per 10,000 in the 27 EU
countries. A similar calculation for the United States indicates
0.797 CF patients per 10,000 people using the very accurate
data of 2005 from the U.S. Cystic Fibrosis Patient Registry
which reports 23,347 patients registered for care in a population
of 293,028,000 [7]. This relatively close agreement, which is
not altogether surprising, helps validate the accuracy of the EU
prevalence value reported herein.
Further calculations from the EU data reveal a variance
[P×(1−P)=0.737×0.263] of 0.194 and a SD of 0.44. Therange of CF prevalence is from 0.104 in Latvia to 2.98 in the
Republic of Ireland (per 10,000). Using the 95% confidence
interval (0→1.5994) for evaluating individual countries indi-
cates that only the Republic of Ireland is an outlier. As the table
shows, Ireland also appears to have the highest incidence at
1:1353 based on registry and survey data [8]. The UK with the
452 P.M. Farrell / Journal of Cystic Fibrosis 7 (2008) 450–453next highest prevalence at 1.37 per 10,000 also has one of the
highest incidence values at 1:2381 [9]. With this in mind, it was
of interest to compare using regression analysis the determined
prevalence and reported incidence figures. In this analysis, we
found that the Pearson correlation coefficient between the
prevalence and incidence data presented in the table is 0.5688
( p=.0057). Also, using regression analysis in an attempt to
predict incidence from prevalence, we found the following
formula — incidence=0.00019+0.00016×prevalence per
10,000 — and a p-value for this model of 0.0015. This sig-
nificant relationship reflects the correlation between prevalence
and incidence and the relative clustering of CF in EU countries.
3. Discussion
In general, the agreement of calculated prevalence values for
a variety of large European countries strongly suggests that the
data are consistent, valid, and as accurate as possible. Also, in
the relatively large European countries that have performed
multiple determinations of the total number of registered CF
patients, the agreement among prevalence values found is
generally satisfactory. For instance, comparing values in the UK
reveals 7046, 7500, 6861 and 8284 patients with CF from a
variety of recent observation periods, while France reported
4140 and 4533, and Belgium registered 859, 860, and 1065
patients in three different tallies.
Although the larger European countries were found to have
data available from a variety of different studies, rather than
combining and averaging these prevalence values, it seems
preferable to use the highest number available, as was done in
the table. This decision was based in part on the fact that not all
CF patients receiving care in some European countries are
registered with cystic fibrosis centers. In fact, information
available from the UK provides an opportunity to adjust the
calculated prevalence data for potential under-reporting to
registries. The adjustment amounts to 14%, i.e., there may be up
to 14% more CF patients in other European countries. However
even with such an adjustment, the calculated prevalence value is
0.840 per 10,000, which is well below the requirement of less
than 5 per 10,000 for orphan designation in the EU. In addition,
the extent of precision is more than satisfactory. Furthermore, it
seems likely that the determined EU prevalence of CF is not
going to change significantly during the next decade because
although CF patients may be living longer [9], smaller families
[10] and prenatal screening will tend to lower the prevalence
[11,12]; however, further research with actuarial modeling will
be necessary to address this issue.
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